Cargando…
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079531/ https://www.ncbi.nlm.nih.gov/pubmed/36807650 http://dx.doi.org/10.1038/s41375-023-01845-9 |
| _version_ | 1785020744872230912 |
|---|---|
| author | Bomben, Riccardo Rossi, Francesca Maria Vit, Filippo Bittolo, Tamara Zucchetto, Antonella Papotti, Robel Tissino, Erika Pozzo, Federico Degan, Massimo Polesel, Jerry Bulian, Pietro Marasca, Roberto Reda, Gianluigi Laurenti, Luca Olivieri, Jacopo Chiarenza, Annalisa Laureana, Roberta Postorino, Massimiliano Del Principe, Maria Ilaria Cuneo, Antonio Gentile, Massimo Morabito, Fortunato Fronza, Gilberto Tafuri, Agostino Zaja, Francesco Foà, Robin Di Raimondo, Francesco Del Poeta, Giovanni Gattei, Valter |
| author_facet | Bomben, Riccardo Rossi, Francesca Maria Vit, Filippo Bittolo, Tamara Zucchetto, Antonella Papotti, Robel Tissino, Erika Pozzo, Federico Degan, Massimo Polesel, Jerry Bulian, Pietro Marasca, Roberto Reda, Gianluigi Laurenti, Luca Olivieri, Jacopo Chiarenza, Annalisa Laureana, Roberta Postorino, Massimiliano Del Principe, Maria Ilaria Cuneo, Antonio Gentile, Massimo Morabito, Fortunato Fronza, Gilberto Tafuri, Agostino Zaja, Francesco Foà, Robin Di Raimondo, Francesco Del Poeta, Giovanni Gattei, Valter |
| author_sort | Bomben, Riccardo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10079531 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100795312023-04-08 Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study Bomben, Riccardo Rossi, Francesca Maria Vit, Filippo Bittolo, Tamara Zucchetto, Antonella Papotti, Robel Tissino, Erika Pozzo, Federico Degan, Massimo Polesel, Jerry Bulian, Pietro Marasca, Roberto Reda, Gianluigi Laurenti, Luca Olivieri, Jacopo Chiarenza, Annalisa Laureana, Roberta Postorino, Massimiliano Del Principe, Maria Ilaria Cuneo, Antonio Gentile, Massimo Morabito, Fortunato Fronza, Gilberto Tafuri, Agostino Zaja, Francesco Foà, Robin Di Raimondo, Francesco Del Poeta, Giovanni Gattei, Valter Leukemia Letter Nature Publishing Group UK 2023-02-18 2023 /pmc/articles/PMC10079531/ /pubmed/36807650 http://dx.doi.org/10.1038/s41375-023-01845-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter Bomben, Riccardo Rossi, Francesca Maria Vit, Filippo Bittolo, Tamara Zucchetto, Antonella Papotti, Robel Tissino, Erika Pozzo, Federico Degan, Massimo Polesel, Jerry Bulian, Pietro Marasca, Roberto Reda, Gianluigi Laurenti, Luca Olivieri, Jacopo Chiarenza, Annalisa Laureana, Roberta Postorino, Massimiliano Del Principe, Maria Ilaria Cuneo, Antonio Gentile, Massimo Morabito, Fortunato Fronza, Gilberto Tafuri, Agostino Zaja, Francesco Foà, Robin Di Raimondo, Francesco Del Poeta, Giovanni Gattei, Valter Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study |
| title | Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study |
| title_full | Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study |
| title_fullStr | Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study |
| title_full_unstemmed | Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study |
| title_short | Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study |
| title_sort | clinical impact of tp53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus cll study |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079531/ https://www.ncbi.nlm.nih.gov/pubmed/36807650 http://dx.doi.org/10.1038/s41375-023-01845-9 |
| work_keys_str_mv | AT bombenriccardo clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT rossifrancescamaria clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT vitfilippo clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT bittolotamara clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT zucchettoantonella clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT papottirobel clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT tissinoerika clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT pozzofederico clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT deganmassimo clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT poleseljerry clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT bulianpietro clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT marascaroberto clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT redagianluigi clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT laurentiluca clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT olivierijacopo clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT chiarenzaannalisa clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT laureanaroberta clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT postorinomassimiliano clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT delprincipemariailaria clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT cuneoantonio clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT gentilemassimo clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT morabitofortunato clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT fronzagilberto clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT tafuriagostino clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT zajafrancesco clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT foarobin clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT diraimondofrancesco clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT delpoetagiovanni clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy AT gatteivalter clinicalimpactoftp53disruptioninchroniclymphocyticleukemiapatientstreatedwithibrutinibacampuscllstudy |